BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP George Eric Davis sold 9,844 shares of BioMarin Pharmaceutical stock in a transaction on Friday, June 23rd. The shares were sold at an average price of $96.60, for a total transaction of $950,930.40. Following the completion of the sale, the executive vice president now owns 93,425 shares in the company, valued at $9,024,855. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

George Eric Davis also recently made the following trade(s):

  • On Monday, June 5th, George Eric Davis sold 9,471 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $91.04, for a total transaction of $862,239.84.
  • On Friday, May 5th, George Eric Davis sold 2,500 shares of BioMarin Pharmaceutical stock. The shares were sold at an average price of $100.34, for a total transaction of $250,850.00.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded down 4.11% during trading on Tuesday, reaching $89.63. 1,580,858 shares of the company were exchanged. The company’s market capitalization is $15.64 billion. BioMarin Pharmaceutical Inc. has a one year low of $73.45 and a one year high of $102.49. The firm’s 50-day moving average is $90.61 and its 200 day moving average is $88.92.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Thursday, May 4th. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.30) by $0.33. The company had revenue of $303.70 million during the quarter, compared to the consensus estimate of $292.58 million. BioMarin Pharmaceutical had a negative return on equity of 22.71% and a negative net margin of 48.43%. The firm’s revenue was up 28.3% on a year-over-year basis. During the same period in the previous year, the company posted ($0.53) EPS. On average, analysts anticipate that BioMarin Pharmaceutical Inc. will post ($0.81) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “BioMarin Pharmaceutical Inc. (BMRN) EVP George Eric Davis Sells 9,844 Shares” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/06/27/biomarin-pharmaceutical-inc-bmrn-evp-george-eric-davis-sells-9844-shares.html.

A number of research analysts have recently commented on the stock. ValuEngine raised shares of BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Jefferies Group LLC reissued a “buy” rating and issued a $116.00 price objective on shares of BioMarin Pharmaceutical in a research report on Monday, May 15th. Cowen and Company reissued a “buy” rating and issued a $150.00 price objective on shares of BioMarin Pharmaceutical in a research report on Monday, May 15th. Wedbush reissued a “hold” rating and issued a $108.00 price objective on shares of BioMarin Pharmaceutical in a research report on Monday, May 8th. Finally, Zacks Investment Research raised shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $107.00 price objective for the company in a research report on Monday, May 1st. Eight analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $111.69.

Several hedge funds and other institutional investors have recently made changes to their positions in BMRN. Norges Bank bought a new position in shares of BioMarin Pharmaceutical during the fourth quarter worth about $83,952,000. Primecap Management Co. CA increased its position in shares of BioMarin Pharmaceutical by 10.5% in the first quarter. Primecap Management Co. CA now owns 8,712,268 shares of the biotechnology company’s stock worth $764,763,000 after buying an additional 826,320 shares during the period. Jennison Associates LLC increased its position in shares of BioMarin Pharmaceutical by 6.7% in the first quarter. Jennison Associates LLC now owns 9,871,207 shares of the biotechnology company’s stock worth $866,495,000 after buying an additional 617,001 shares during the period. Vanguard Group Inc. increased its position in shares of BioMarin Pharmaceutical by 3.7% in the first quarter. Vanguard Group Inc. now owns 13,702,404 shares of the biotechnology company’s stock worth $1,202,796,000 after buying an additional 495,118 shares during the period. Finally, MARSHALL WACE ASIA Ltd bought a new position in shares of BioMarin Pharmaceutical during the first quarter worth about $37,416,000. Institutional investors own 96.61% of the company’s stock.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Insider Buying and Selling by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.